Literature DB >> 23590181

Preliminary results of the generation of a shortened quality-of-life assessment for patients with advanced cancer: the FACIT-Pal-14.

Liang Zeng1, Gillian Bedard, David Cella, Nemica Thavarajah, Emily Chen, Liying Zhang, Margaret Bennett, Kenneth Peckham, Sandra De Costa, Jennifer L Beaumont, May Tsao, Cyril Danjoux, Elizabeth Barnes, Arjun Sahgal, Edward Chow.   

Abstract

OBJECTIVE: Shortened quality-of-life (QOL) tools are advantageous in palliative care patients. Development of such tools begins with the identification of issues relevant to a population. The purpose of this study was to identify the most important items of the Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-Pal) to create an abbreviated questionnaire for future palliative care trials.
METHODS: A convenience sample of patients and health care professionals (HCPs) assessed the relevance of each item of the FACIT-Pal and whether they would include the item in a final questionnaire. Patients and HCPs identified their top 10 most important issues and were asked whether items were inappropriate, upsetting, or irrelevant; a shortened questionnaire was generated from this input.
RESULTS: Sixty patients and 56 HCPs participated. The median score in the Karnofsky Performance Scale (KPS) of patients was 70, and the majority of HCPs were radiation oncologists. The 46-item questionnaire was shortened to 14 questions, retaining several items from the Functional Assessment of Cancer Therapy-General (FACT-G) as well as issues pertaining specifically to palliative care patients. Items within the emotional, physical, and functional well-being subscales were retained along with those for various symptoms including constipation, nausea, dyspnea, and sleep. No new content beyond what is covered by the FACIT-Pal was identified consistently by either HCPs or patients. Similarly, no item was consistently rated as being inappropriate, upsetting, or irrelevant in the 14-item questionnaire.
CONCLUSION: The FACIT-Pal-14, a shortened 14-item questionnaire has been generated for the palliative care population. Future studies should complete psychometric validation of this instrument for the assessment of QOL in palliative care patients.

Entities:  

Mesh:

Year:  2013        PMID: 23590181     DOI: 10.1089/jpm.2012.0595

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  11 in total

1.  Measuring health-related quality of life in patients with advanced cancer: a systematic review of self-administered measurement instruments.

Authors:  Janneke van Roij; Heidi Fransen; Lonneke van de Poll-Franse; Myrte Zijlstra; Natasja Raijmakers
Journal:  Qual Life Res       Date:  2018-02-10       Impact factor: 4.147

2.  Which quality of life instruments are preferred by cancer patients in Japan? Comparison of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and the Functional Assessment of Cancer Therapy-General.

Authors:  Kazuki Sato; Megumi Shimizu; Mitsunori Miyashita
Journal:  Support Care Cancer       Date:  2014-05-28       Impact factor: 3.603

3.  Psychometric Properties of the FACIT-Pal 14 Administered in an Outpatient Palliative Care Clinic.

Authors:  Myrick C Shinall; E Wesley Ely; Mohana Karlekar; Samuel G Robbins; Rameela Chandrasekhar; Sara F Martin
Journal:  Am J Hosp Palliat Care       Date:  2018-03-12       Impact factor: 2.500

4.  How effective is virtual reality technology in palliative care? A systematic review and meta-analysis.

Authors:  Jiping Mo; Victoria Vickerstaff; Ollie Minton; Simon Tavabie; Mark Taubert; Patrick Stone; Nicola White
Journal:  Palliat Med       Date:  2022-05-30       Impact factor: 5.713

5.  Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7).

Authors:  Madeleine T King; Meera Agar; David C Currow; Janet Hardy; Belinda Fazekas; Nikki McCaffrey
Journal:  Support Care Cancer       Date:  2019-04-16       Impact factor: 3.603

6.  A lay navigator-led, early palliative care intervention for African American and rural family caregivers of individuals with advanced cancer (Project Cornerstone): Results of a pilot randomized trial.

Authors:  J Nicholas Dionne-Odom; Andres Azuero; Richard A Taylor; Chinara Dosse; Avery C Bechthold; Erin Currie; Rhiannon D Reed; Erin R Harrell; Sally Engler; Deborah B Ejem; Nataliya V Ivankova; Michelle Y Martin; Gabrielle B Rocque; Grant R Williams; Marie A Bakitas
Journal:  Cancer       Date:  2021-12-07       Impact factor: 6.921

7.  Development and validation of the quality care questionnaire -palliative care (QCQ-PC): patient-reported assessment of quality of palliative care.

Authors:  Young Ho Yun; Eun Kyo Kang; Jihye Lee; Jiyeon Choo; Hyewon Ryu; Hye-Min Yun; Jung Hun Kang; Tae You Kim; Jin-Ah Sim; Yaeji Kim
Journal:  BMC Palliat Care       Date:  2018-03-05       Impact factor: 3.234

8.  More comprehensively measuring quality of life in life-threatening illness: the McGill Quality of Life Questionnaire - Expanded.

Authors:  S Robin Cohen; Lara B Russell; Anne Leis; Javad Shahidi; Pat Porterfield; David R Kuhl; Anne M Gadermann; Richard Sawatzky
Journal:  BMC Palliat Care       Date:  2019-10-31       Impact factor: 3.234

9.  Collaborative advance care planning in advanced cancer patients: col-ACP -study - study protocol of a randomised controlled trial.

Authors:  Carola Seifart; Martin Koch; Nico Leppin; Katharina Nagelschmidt; Jorge Riera Knorrenschild; Nina Timmesfeld; Winfried Rief; Pia von Blanckenburg
Journal:  BMC Palliat Care       Date:  2020-08-24       Impact factor: 3.234

10.  A technology-enhanced model of care for transitional palliative care versus attention control for adult family caregivers in rural or medically underserved areas: study protocol for a randomized controlled trial.

Authors:  Diane E Holland; Catherine E Vanderboom; Jay Mandrekar; Bijan J Borah; Ann Marie Dose; Cory J Ingram; Joan M Griffin
Journal:  Trials       Date:  2020-10-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.